Mereo BioPharma Group PLC ADR

Stock Chart, Company Information, and Scan Results

$1.77(as of Sep 5, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Mereo BioPharma Group PLC ADR Company Information, Fundamentals, and Technical Indicators

Stock Price$1.77
Ticker SymbolMREO
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees36
CountyUSA
Market Cap$281.6M
EBIDTA-44.0M
10-Day Moving Average1.74
P/E Ratio-5.71
20-Day Moving Average1.70
Forward P/E Ratio0.00
50-Day Moving Average1.90
Earnings per Share-0.30
200-Day Moving Average2.59
Profit Margin-2,923.20%
RSI51.08
Shares Outstanding159.1M
ATR0.09
52-Week High4.72
Volume1,012,532
52-Week Low1.47
Most Recent Support Level1.68
Book Value54.2M
Most Recent Resistance Level1.83
P/B Ratio5.22
Upper Keltner1.91
P/S Ratio180.92
Lower Keltner1.48
Debt-to-Equity Ratio1.91
Next Earnings Date11/18/2025
Cash Surplus48.6M
Next Ex-Dividend DateUnknown

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Mereo BioPharma Group PLC ADR In Our Stock Scanner

As of Sep 08, 2025
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Morning StarScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.